This infographic summarizes the findings from the IQ consortium survey on the use of preclinical PK/PD modeling in the pharmaceutical industry.

1. 68% of companies use preclinical
PK/PD analysis in all therapeutic areas.
of surveyed companies use
Phoenix®
WinNonlin®
for
preclinical PK/PD modeling.
of surveyed companies use Simcyp®
for PBPK analysis.
86% of companies have seen preclinical
PK/PD analysis impact drug development.
For more information, visit www.certara.com
Source: Schuck E, Bohnert T, Chakravarty A, Damian-Iordache V, Gibson C, Hsu CP, et al.
Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation
in the Pharmaceutical Industry: An IQ Consortium Survey
Examining the Current Landscape. AAPS J. 2015.
© Copyright Certara 2015
IG0215-US-01
IQ Consortium Survey:
Preclinical PK/PD Modeling in the
Pharmaceutical Industry
73% of companies include
preclinical PK/PD analysis in
regulatory submissions.
100%
86%